Ziftomenib 200 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 200 mg

Reference Brands: Komzifti (USA)

Category: Oncology Cancer Care

Ziftomenib is a small‑molecule menin inhibitor. It blocks the interaction between menin and MLL proteins, disrupting a pathway critical for the survival and proliferation of certain leukemia cells, especially those with NPM1 mutation or MLL rearrangement. It is used in adult patients with relapsed or refractory AML who have no satisfactory alternative treatment options.

Product Description:

Ziftomenib inhibits menin, a scaffold protein that is not itself an oncogene but is indispensable to one. In leukaemias driven by KMT2A rearrangement or NPM1 mutation, menin anchors the leukaemogenic complex to chromatin and keeps a set of developmental genes switched on, locking the cell in an immature, self-renewing state. Breaking the menin interaction releases that block and the cells differentiate into mature myeloid cells rather than simply dying.

It is used for relapsed or refractory acute myeloid leukaemia with the relevant mutations, where outcomes have been poor and few options exist. Because the mechanism is differentiation rather than cytotoxicity, the characteristic risk is differentiation syndrome — fever, dyspnoea, hypoxia, effusions and oedema as a large mass of blasts matures at once — which requires prompt recognition and corticosteroid treatment. QT prolongation requires ECG monitoring; cytopenias and infection occur.

Sourcing notes. Recently approved originator product, on patent, with registration so far in a limited number of territories — verify before quoting. Requires NPM1 or KMT2A testing at the destination. Treating centres need familiarity with differentiation syndrome, which is otherwise easily mistaken for sepsis or fluid overload. Oral capsules, room temperature.